United Health Products, Inc. develops CelluSTAT®, a patented hemostatic gauze cleared for superficial bleeding but currently seeking FDA Premarket Approval (PMA) for Class III surgical applications. The company has recorded no product revenue since at least 2022, sustaining operating losses driven by regulatory, clinical, and development expenses. Its near-term growth depends on resolving regulatory deficiencies identified by the FDA and securing commercial partnerships or strategic transactions. Liquidity remains tight, with financing arrangements from Alumni Capital supporting ongoing operations. The company faces significant risks including regulatory uncertainty, competitive pressures, and operational challenges tied to manufacturing and internal controls.